| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $24,999,997 | 2 | 100 |
Sells | $0 | 0 | 0 |
| Bonita David P | 1 | $12.5M | 0 | $0 | $12.5M | |
| ORBIMED ADVISORS LLC | 1 | $12.5M | 0 | $0 | $12.5M |
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic …
Over the last 12 months, insiders at Prelude Therapeutics Incorporated have bought $25M and sold $0 worth of Prelude Therapeutics Incorporated stock.
On average, over the past 5 years, insiders at Prelude Therapeutics Incorporated have bought $9.07M and sold $455,784 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bonita David P () — $12.5M. ORBIMED ADVISORS LLC () — $12.5M.
The last purchase of 2,815,315 shares for transaction amount of $12.5M was made by ORBIMED ADVISORS LLC () on 2026‑04‑21.
| 2026-04-21 | ORBIMED ADVISORS LLC | 2.82M 4.8551% | $4.44 | $12.5M | -4.87% | |||
| 2026-04-21 | Bonita David P | 2.82M 4.8551% | $4.44 | $12.5M | -4.87% | |||
| 2025-03-25 | Vaddi Krishna | CEO | 675,000 1.2187% | $0.69 | $467,438 | +79.75% | ||
| 2025-03-25 | Combs Andrew | Chief Chemistry Officer | 100,000 0.1806% | $0.69 | $69,250 | +79.75% | ||
| 2025-03-21 | Vaddi Krishna | CEO | 15,000 0.028% | $0.73 | $10,959 | +72.39% | ||
| 2025-03-20 | Vaddi Krishna | CEO | 5,416 0.0097% | $0.73 | $3,950 | +65.65% | ||
| 2025-03-17 | Vaddi Krishna | CEO | 9,106 0.0164% | $0.75 | $6,829 | +60.29% | ||
| 2025-03-14 | Vaddi Krishna | CEO | 29,999 0.0447% | $0.75 | $22,631 | +61.12% | ||
| 2025-03-13 | Vaddi Krishna | CEO | 50,000 0.0921% | $0.72 | $35,820 | +68.34% | ||
| 2025-03-12 | Vaddi Krishna | CEO | 47,500 0.0881% | $0.71 | $33,744 | +70.93% | ||
| 2024-12-31 | Vaddi Krishna | CEO | 5,000 0.0087% | $1.21 | $6,044 | -21.86% | ||
| 2024-12-30 | Vaddi Krishna | CEO | 10,000 0.0163% | $1.20 | $12,000 | -17.99% | ||
| 2024-12-23 | Combs Andrew | Chief Chemistry Officer | 60,000 0.1202% | $1.37 | $82,002 | -19.97% | ||
| 2024-12-20 | Combs Andrew | Chief Chemistry Officer | 3,075 0.0055% | $1.15 | $3,536 | -24.25% | ||
| 2024-12-19 | Vaddi Krishna | CEO | 6,888 0.0122% | $0.89 | $6,116 | +11.75% | ||
| 2024-12-19 | Lim Bryant David | CLO, Interim CFO, Corp Sec. | 25,000 0.0452% | $0.91 | $22,638 | +11.75% | ||
| 2024-12-18 | Vaddi Krishna | CEO | 100,000 0.1882% | $0.93 | $93,210 | +8.51% | ||
| 2023-05-25 | Vaddi Krishna | CEO | 900 0.0019% | $5.31 | $4,779 | -28.14% | ||
| 2023-05-24 | Vaddi Krishna | CEO | 1,000 0.002% | $5.01 | $5,011 | -26.55% | ||
| 2023-05-24 | Lim Bryant David | Chief Legal Officer, Corp Sec. | 2,400 0.0053% | $5.39 | $12,936 | -26.55% |
| ORBIMED ADVISORS LLC | 11808945 20.4025% | $44.64M | 6 | 0 | <0.0001% | |
| Bonita David P | 11808945 20.4025% | $44.64M | 6 | 0 | +8.96% | |
| BAKER BROS. ADVISORS LP | 5212371 9.0055% | $19.7M | 4 | 0 | +34.76% | |
| Vaddi Krishna | CEO | 1999296 3.4542% | $7.56M | 15 | 0 | +24.47% |
| Combs Andrew | Chief Chemistry Officer | 480123 0.8295% | $1.81M | 6 | 0 | <0.0001% |
| FRIEDMAN PAUL A | director | 152576 0.2636% | $576,737.28 | 1 | 0 | |
| Chardonnet Laurent | Chief Financial Officer | 42165 0.0728% | $159,383.70 | 3 | 0 | +5.29% |
| Lim Bryant David | CLO, Interim CFO, Corp Sec. | 27400 0.0473% | $103,572.00 | 2 | 0 | <0.0001% |
| Dier Mardi | director | 10000 0.0173% | $37,800.00 | 1 | 0 | +34.76% |
| Pierce Christopher | EVP and Chief of Business Oper | 3750 0.0065% | $14,175.00 | 1 | 4 | +34.76% |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 444 0.0008% | $1,678.32 | 1 | 5 | +34.76% |
$22,710,871 | 107 | 8.53% | $220.62M | |
$6,146,922 | 96 | -4.70% | $233.68M | |
$19,239,249 | 50 | -2.24% | $238.33M | |
Prelude Therapeutics Incorporated (PRLD) | $168,352,523 | 35 | 13.58% | $218.79M |
$54,828,550 | 26 | -13.88% | $201.12M |
| Increased Positions | 24 | +43.64% | 3M | +8.97% |
| Decreased Positions | 23 | -41.82% | 2M | -4.99% |
| New Positions | 10 | New | 2M | New |
| Sold Out Positions | 8 | Sold Out | 209,746 | Sold Out |
| Total Postitions | 56 | +1.82% | 34M | +3.99% |
| Orbimed Advisors Llc | $45,289.00 | 37.7% | 16.59M | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $27,638.00 | 23.01% | 10.12M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $3,131.00 | 2.61% | 1.15M | +898,621 | +361.73% | 2025-09-30 |
| Vanguard Group Inc | $2,710.00 | 2.26% | 992,854 | +60,284 | +6.46% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $2,392.00 | 1.99% | 876,338 | -51,270 | -5.53% | 2025-09-30 |
| Renaissance Technologies Llc | $1,485.00 | 1.24% | 544,000 | -37,800 | -6.5% | 2025-09-30 |
| Acadian Asset Management Llc | $1,476.00 | 1.23% | 540,565 | 0 | 0% | 2025-09-30 |
| Morgan Stanley | $776.00 | 0.65% | 284,203 | -179 | -0.06% | 2025-09-30 |
| Blackrock, Inc. | $723.00 | 0.6% | 264,973 | -167,586 | -38.74% | 2025-09-30 |
| Two Sigma Advisers, Lp | $608.00 | 0.51% | 222,700 | -2,300 | -1.02% | 2025-09-30 |